ARA-290 (also known as cibinetide) is an 11-amino acid peptide derived from the beta common receptor (βcR) binding domain of erythropoietin (EPO). It was designed to activate the innate repair receptor (IRR), a heteromer of the EPO receptor and βcR, without the erythropoietic activity of full-length EPO.
Innate Repair Receptor
The IRR is a tissue-protective receptor complex distinct from the classical erythropoietic EPO receptor. When activated by ARA-290, it triggers anti-inflammatory and tissue-protective signaling cascades including the JAK2/STAT5 and PI3K/Akt pathways.
Separation of Activities
By targeting only the IRR and not the homodimeric EPO receptor responsible for erythropoiesis, ARA-290 provides cytoprotective effects without increasing red blood cell production. This selectivity is achieved through the peptide’s mimicry of the specific EPO helix that contacts the βcR subunit.